Strategic Partners

Pfizer is a leading research-based biopharmaceutical company, and has made an equity investment in Cellectis. Together, we are collaborating globally on 15 targets, including the first allogeneic BCMA CAR-T, which can have powerful activity against cancers like measurable multiple myeloma.

“Cellectis and Pfizer share the same commitment to develop unique allogeneic cancer therapies that will benefit patients around the world. Combining Cellectis’ innovative allogeneic cell approach and scientific gene modification expertise with Pfizer’s deep oncology and immunology experience in translating discovery into patient impact, creates a world-class partnership designed to advance a new generation of CAR-T immunotherapies for cancer patients with urgent medical needs.”

Mikael Dolsten, MD, PhD, President of Worldwide Research & Development at Pfizer

Servier is the leading French independent pharmaceutical company. Cellectis and Servier are collaborating on five targets, including UCART19, with ongoing pediatric and adult trials sponsored by Servier in the UK.

"Collaborating closely with Cellectis on UCART19, an innovative cellular therapy candidate against lymphoid malignancies, Servier’s team constantly explores new horizons and delivers the utmost best of their expertise. Together, our highly complementary competencies and know-how give our teams the best chances of providing patients worldwide with a new generation of cancer treatments they need."

                Olivier Laureau, President of Servier

World-Class Clinical Centers

Weill Cornell Medicine, NewYork-Presbyterian Hospital, was ranked in 2016 as New York’s No. 1 hospital for the 16th year in a row, and No. 6 ranked hospital in the United States.

Cellectis is closely working with Weill Cornell Medicine on the development of UCART123 for Acute Myeloid Leukemia (AML).

The Phase 1 clinical trial with UCART123 in patients with AML is led by principal investigator Dr. Gail J. Roboz, Professor of Medicine at Weill Cornell Medicine and Director of the Clinical and Translational Leukemia Programs at Weill Cornell Medicine and NewYork-Presbyterian.

MD Anderson Cancer Center is ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report’s “Best Hospitals” survey.

Cellectis and MD Anderson are developing UCART123 for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

The UCART123 clinical program for BPDCN is led by Dr. Naveen Pemmaraju, MD, Assistant Professor, and Professor Hagop Kantarjian, MD, Department Chair, Department of Leukemia, Division of Cancer Medicine.

Exclusive License

The University of Minnesota granted Cellectis an exclusive license to TALEN® gene editing technology. TALEN® enables the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more.